

April 25, 2024**Contents**

| | |
|--------------------------------------|----|
| Clinical Profile Documentation | 2 |
| AJCC Version 8 Staging..... | 2 |
| Problem Groups..... | 3 |
| Additions..... | 3 |
| Updates | 3 |
| Problems..... | 4 |
| Additions..... | 4 |
| Procedures..... | 4 |
| Additions..... | 4 |
| Lab Analytes & Panels..... | 4 |
| Additions and Updates | 4 |
| Medications..... | 6 |
| Additions..... | 6 |
| Updates | 6 |
| Regimen Library..... | 7 |
| Additions..... | 7 |
| Updates | 8 |
| Renames | 9 |
| Research..... | 9 |
| Updates | 9 |
| Billing & HCPCS Codes | 9 |
| Updates | 9 |
| NDC to HCPCS Crosswalk | 10 |
| Additions..... | 10 |
| Appendix A..... | 10 |
| Problem & Codes Summary..... | 10 |
| Additions | 10 |

Clinical Profile Documentation

AJCC Version 8 Staging

This release contains updated **TNM** values, **Staging Groups**, and **Template** functionality to align with AJCC version 8 conditions for:

- **Lymphoma, Non-Hodgkin (NHL), Primary Cutaneous Lymphoma, Mycosis Fungoides/Sezary Syndrome**

Users will see updated values and descriptions for **Tumor Type (T)**, **Node (N)**, **Metastasis (M)**, and **Peripheral Blood Involvement (B)** documentation points for **Lymphoma, Non-Hodgkin (NHL), Primary Cutaneous Lymphoma, Mycosis Fungoides/Sezary Syndrome**.

The following values are no longer available:

- **T1, T2, TX**
- **N1, N2**
- **M0, M1**
- **B0, B1**

The following documentation points now have updated descriptions:

- **N1a, N1b, N2a, N2b**
- **cM0, cM1, pM1**
- **B0a, B0b, B1a, B1b, B2**

The staging calculator will display updated **Stage** values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

| Tumor Type | Node | Metastasis | Blood | Stage |
|------------|------|------------|-------|-------|
| T1 | N0 | M0 | B0,1 | IA |
| T2 | N0 | M0 | B0,1 | IB |
| T1,2 | N1,2 | M0 | B0,1 | IIA |
| T3 | N0-2 | M0 | B0,1 | IIB |
| T4 | N0-2 | M0 | B0 | IIIA |
| T4 | N0-2 | M0 | B1 | IIIB |
| T1-4 | N0-2 | M0 | B2 | IVA1 |

| Tumor Type | Node | Metastasis | Blood | Stage |
|------------|------|------------|-------|-------|
| T1-4 | N3 | M0 | B0-2 | IVA2 |
| T1-4 | N0-3 | M1 | B0-2 | IVB |

Problem Groups

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

FOLR1 (Folate receptor alpha) expression is now available for **Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer** with the following documentation points:

- Positive ($\geq 75\%$)
- Negative ($< 75\%$)
- Unknown

Updates

Problem **Malignant tumor of female genital organ (disorder)** was added to Problem Group **Solid Tumors (Parent) (excluding HL/NHL/Solid Other)** to support documentation of **TMB (Tumor mutational burden)**.

Melanoma, Uvea, Ciliary Body/Choroid has been assigned a **pathway (PW)** designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping.

The following problems now have **PW** to the left of the problem in the search results:

- Malignant melanoma of ciliary body (disorder)
- Malignant melanoma of choroid (disorder)
- Ring melanoma of ciliary body (disorder)
- Malignant melanoma of uveal tract (disorder)
- Malignant melanoma of left choroid (disorder)
- Malignant melanoma of right choroid (disorder)

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Please see **APPENDIX A** for a complete summary of changes.

Procedures

Additions

New items are available for documentation in **Procedures** and appear in the **Charge Capture Report (CCR)**.

- Colposcopy of cervix including upper/adjacent vagina + biopsy(s) of cervix + ECC mapped to 57454
- Colposcopy of cervix including upper/adjacent vagina + biopsy(s) of cervix mapped to 57544
- ECC (not as part of D&C) (57505) mapped to 57505

Lab Analytes & Panels

Additions and Updates

- -5/5q- by FISH
- -7/7q- by FISH

- +8 by FISH
- 20q12 by FISH
- Alpha globin gene released by
- Alpha globin gene result summary
- Alpha globin gene specimen
- ANA additional pattern titer
- Anti-SAE1 Ab, IgG, units
- DRVVT complete panel
- Factor 12 assay panel
- Factor II assay panel

- Factor X assay panel
- Factor X, %
- Factor XI assay panel
- Factor XII assay, %
- Folate, RBC, ng/mL
- H. pylori Ab, IgG, U
- Herpes simplex virus II specific Ab, IgG, AI
- High risk HPV with genotype 16,18 panel
- Histoplasma antigen, urine interpretation
- Histoplasma antigen, urine specimen
- Histoplasma antigen, urine, ng/ml
- HLA-A 02:01
- HPV mRNA E6/E7, rectal
- HPV, other HR types
- IgH by NGS
- IgH gene rearrangement by NGS panel
- Immunofixation, isatuximab-specific, serum panel
- KIT D816V digital PCR, systemic mastocytosis
- Lymphoma immunohisto. analysis
- Lymphoma immunohisto. analysis panel
- MAG antibody, IGM panel
- MAG antibody, IGM, titer
- MPL EXON 10 mutation detection, V panel
- Myeloid disorder immunohisto.
- Myeloid disorder immunohisto. panel
- NeoGenomics panel
- Neutrophil associated Ab clinical relevance
- Neutrophil associated Ab electronic signature
- Neutrophil associated Ab methodology
- Neutrophil associated Ab reference
- Neutrophil, smear, urine
- Onkosight advanced plasma cell myeloma NGS comment
- Onkosight advanced plasma cell myeloma NGS detailed genetic interpretation 1
- OnkoSight advanced plasma cell myeloma NGS panel
- Onkosight advanced plasma cell myeloma NGS technical summary
- Onkosight NGS ABL1 sequencing
- Onkosight NGS ABL1 sequencing interpretation
- Onkosight NGS ABL1 sequencing methods
- Onkosight NGS ABL1 sequencing panel

- Onkosight NGS ABL1 sequencing references
- Onkosight NGS ABL1 sequencing report footer
- P53 by FISH panel
- Parvovirus B19 PCR source
- PEth 16:0/18:1 (POPEth) by LC MS/MS, ng/mL
- PEth 16:0/18:2 (PLPEth) by LC MS/MS, ng/mL
- PEth interpretation
- Phosphatidylethanol (PEth) confirmation, blood panel
- siParadigm panel
- SPEP/IFE interpretation
- T-cell gene rearrangement, PCR diagnosis
- T-cell gene rearrangement, PCR signing pathologist
- Thinprep pap smear panel
- Wound fungus culture
- Wound fungus culture panel
- Wound, aerobic culture
- Wound, aerobic culture panel
- Wound, anaerobic culture
- Wound, anaerobic culture panel

Medications

Additions

- AO-252 invest Oral
- JS001/TAB001 invest IV
- JS004/TAB004 invest IV
- M4076 invest Oral
- PC14586 invest Oral
- PF-07329640 invest IV
- RMC-6291 invest Oral
- Tifcemalimab invest (JS004/TAB004 invest IV)
- Toripalimab invest (JS001/TAB001 invest IV)

Updates

| Medication | Update |
|-------------------|---|
| AB801 invest Oral | New Form available: 40 mg tablet |

| Medication | Update |
|---------------------------------|--|
| M1774 invest Oral | New Form available: 30 mg tablet |
| Pemetrexed IV | <p>New Rounding Rule available: 100 mg</p> <p>New Maximum Single Dose (flat) available: 1,250 mg</p> <p>New Quick Sig Picks available:</p> <ul style="list-style-type: none"> • Default Sig: Pemetrexed 500 mg/m² intravenously Piggyback once; administer over 10 minutes • Pemetrexed 500 mg/m² intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL. NOTE: This product is equivalent to Alimta • Pemetrexed 500 mg/m² intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL. NOTE: This product is equivalent to Pemfexy • Pemetrexed 500 mg/m² intravenously Piggyback once; administer over 10 minutes; Use empty IV bag. Do not further dilute. NOTE: This product is equivalent to Pemrydi RTU |
| PF-06801591 invest IV | New Alias available: Sasanlimab invest |
| PF-06801591 invest Subcutaneous | New Form available: 150 mg/mL (2 mL) pre-filled syringe |
| Sasanlimab invest Subcutaneous | New Medication Term available: PF-06801591 invest Subcutaneous |

Regimen Library

Additions

| Regimen Name | Diagnosis |
|---|--|
| Capecitabine D1-14 + Trastuzumab IV Q21D (Esophageal, Gastric) | Gastric Cancer; Esophageal Cancer (Parent) |
| Cyclophosphamide (60 mg/kg) D1-2 + Fludarabine (25 mg/m ²) D3-7 (TIL Therapy Lymphodepletion) | Melanoma, Skin |
| Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2) | Multiple Myeloma (MM) |
| Gemcitabine D1,8 + Cisplatin Q21D (Uterine) | Uterine Cancer (Parent) |

| Regimen Name | Diagnosis |
|---|-------------------------------------|
| Infliximab SQ D1,15 (Maintenance) Q28D | Crohn's Disease; Ulcerative Colitis |
| Lifileucel (Amtagvi TIL) fb IL-2 Off-Site Documentation | Melanoma, Skin |

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Anal Cancer (Parent)
- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Hepatocellular Carcinoma (HCC)
- Lung Cancer, Non-small Cell (SCLC)
- Lung Cancer, Small Cell (NSCLC)
- Lymphoma, Hodgkin (HL)
- Malignant Mesothelioma
- Malignant Pleural Mesothelioma
- Melanoma, Ciliary Body/Choroid
- Melanoma, Skin
- Merkel Cell Carcinoma
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Urethral Cancer
- Uterine Cancer (Parent)

Renames

| Previous Name | New Name |
|--|---|
| Capecitabine D1-14 + Trastuzumab IV Q21D | Capecitabine D1-14 + Trastuzumab IV Q21D (Breast) |

Research

Updates

| | Updated Reference Information | | | |
|------------|--|---|--|---|
| | Updated Drug Service Order Information | | | |
| | Updated Regimen Instructions | | | |
| | Other Changes | | | |
| USOR 19062 | X | X | | |
| USOR 20336 | X | | | |
| USOR 21493 | X | | | |
| USOR 22101 | X | | | |
| USOR 22167 | X | X | | |
| USOR 22245 | | | | Now available: USOR 22245 Part 1b NGM707 + Pembrolizumab Q21D |
| USOR 22249 | X | | | |
| USOR 23091 | X | | | |

Billing & HCPCS Codes

Updates

| Medication | HCPCS Codes |
|--------------------------------------|----------------------------------|
| atidarsagene autotemcel IV | J3590 per 6.6 x 10e6 CD34+ cells |
| immune globulin, gamma (IgG)-stwk IV | J3590 per 500 mg |
| infliximab-dyyb Subcutaneous | J3590 per 120 mg |
| Pemetrexed (pemrydi rtu) | J9324 per 10 mg |

| Medication | HCPCS Codes |
|-------------------------------|-----------------|
| Spesolimab-sbzo Subcutaneous | J1747 per 1 mg |
| Sotatercept-csrk Subcutaneous | J3590 per 45 mg |

NDC to HCPCS Crosswalk

Additions

| Medication (Brand) | HCPCS Code | NDC |
|------------------------------|-----------------|----------------------------|
| Pemetrexed (pemrydi rtu) | J9324 per 10 mg | 70121245301 70121246101 |
| Spesolimab-sbzo Subcutaneous | J1747 per 1 mg | 00597003510 |

Appendix A

Problem & Codes Summary

Additions

| Problem | ICD-10 Codes |
|--|---|
| Encounter for antineoplastic immunotherapy | Z51.12 Encounter for antineoplastic immunotherapy |
| Long-term current use of aromatase inhibitor | Z79.811 - Long term (current) use of aromatase inhibitors |
| Prostate cancer | C61 - Malignant neoplasm of prostate |